U.S. Markets open in 3 hrs 27 mins

Can You Imagine How IRadimed's (NASDAQ:IRMD) Shareholders Feel About The 94% Share Price Increase?

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). For example, the IRadimed Corporation (NASDAQ:IRMD) share price is up 94% in the last year, clearly besting than the market return of around 6.5% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Looking back further, the stock price is 46% higher than it was three years ago.

See our latest analysis for IRadimed

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

IRadimed boasted truly magnificent EPS growth in the last year. While that particular rate of growth is unlikely to be sustained for long, it is still remarkable. So we'd expect to see the share price higher. Strong growth like this can be evidence of a fundamental inflection point in the business, making it a good time to investigate the stock more closely.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

NasdaqCM:IRMD Past and Future Earnings, March 27th 2019

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

We're pleased to report that IRadimed rewarded shareholders with a total shareholder return of 94% over the last year. So this year's TSR was actually better than the three-year TSR (annualized) of 13%. Given the track record of solid returns over varying time frames, it might be worth putting IRadimed on your watchlist. Before spending more time on IRadimed it might be wise to click here to see if insiders have been buying or selling shares.

But note: IRadimed may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.